Dare Bioscience (NASDAQ: DARE) reported Q1 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $9.3 million versus the consensus estimate of $173.67 thousand.

For earnings history and earnings-related data on Dare Bioscience (DARE) click here.